ODAD4: A Promising Drug Target for Neurological Conditions (G83538)

Target Name: ODAD4

NCBI ID: G83538

ODAD4

ODAD4: A Promising Drug Target for Neurological Conditions

ODAD4 (TTC25) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and kidneys. It is a key regulator of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain.

ODAD4 is also known as TTC25 because it is a transmembrane protein that spans the inner and outer membranes of the blood-brain barrier. This makes it an attractive target for drugs that want to enter the brain and interact with its unique structure.

One of the reasons that ODAD4 is a promising drug target is its role in the development and progression of several neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These conditions are characterized by the accumulation of abnormal proteins in the brain, which can cause progressive neurodegeneration and damage to the brain.

In addition to its role in the development of neurological conditions, ODAD4 is also a potential biomarker for these conditions. By measuring the level of ODAD4 in brain tissue, researchers can track the progression of these conditions and monitor the effectiveness of potential treatments.

ODAD4 is also a target for drug discovery because of its unique structure and the fact that it is expressed in multiple tissues. This makes it difficult for drugs to interact with it and introduces a challenge for researchers to identify small molecules that can inhibit its activity.

In addition to its potential as a drug target, ODAD4 is also a potential biomarker for several other conditions. For example, it is expressed in the lungs, kidneys, and heart, which makes it a potential target for drugs that want to improve respiratory function, kidney function, and cardiovascular health.

ODAD4 is also a potential target for the treatment of insomnia, as it has been shown to be involved in the regulation of sleep and wakefulness. This makes it a promising target for drugs that want to improve sleep quality and reduce the symptoms of insomnia.

In conclusion, ODAD4 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of the blood-brain barrier. It is also a potential drug target and biomarker for several neurological and psychiatric conditions. Further research is needed to fully understand its role and potential as a therapeutic target.

Protein Name: Outer Dynein Arm Docking Complex Subunit 4

Functions: Component of the outer dynein arm-docking complex (ODA-DC) that mediates outer dynein arms (ODA) binding onto the doublet microtubule. Plays an essential role for the assembly of ODA-DC and for the docking of ODA in ciliary axoneme

The "ODAD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ODAD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets